Genetic architecture of lung cancer revealed by common and rare variant analyses across population-scale biobanks.
Whole genome sequencing reveals rare genetic variations affecting lung cancer risk beyond what earlier genetic methods captured, refining inherited risk assessment.
This landmark multi-biobank WGS study combining UK Biobank, 100,000 Genomes Project, and All of Us data is the largest genetic architecture study of lung cancer to date, identifying novel rare non-coding variant associations that extend beyond what GWAS and exome sequencing capture. The findings establish rare non-coding variation as a meaningful contributor to lung cancer susceptibility and provide a framework for incorporating WGS into lung cancer polygenic risk stratification.
What the study was
- Study design
- Whole-genome sequencing genetic association study (multi-biobank)
- Population
- 52,550 lung cancer cases and 1,617,173 controls across UK Biobank, 100,000 Genomes Project, and All of Us
- Sample size
- 1669723
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- NPJ precision oncology
Why it surfaced
Largest WGS lung cancer genetic association study (>1.6M controls) extends lung cancer susceptibility beyond GWAS and exome sequencing; rare non-coding variants identified may contribute to polygenic risk score development for lung cancer screening.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.